Table 1.
Association between MICAL-L2 expression and clinicopathologic features in the validation cohort
| Characteristic | levels | Low expression of MICALL2 | High expression of MICALL2 | p |
|---|---|---|---|---|
| n | 227 | 227 | ||
| T stage, n (%) | T1 | 4 (0.9%) | 7 (1.5%) | 0.389 |
| T2 | 43 (9.5%) | 34 (7.5%) | ||
| T3 | 155 (34.2%) | 154 (34%) | ||
| T4 | 24 (5.3%) | 32 (7.1%) | ||
| N stage, n (%) | N0 | 140 (30.8%) | 127 (28%) | 0.301 |
| N1 | 52 (11.5%) | 53 (11.7%) | ||
| N2 | 35 (7.7%) | 47 (10.4%) | ||
| M stage, n (%) | M0 | 164 (41.3%) | 169 (42.6%) | 0.666 |
| M1 | 34 (8.6%) | 30 (7.6%) | ||
| Pathologic stage, n (%) | Stage I | 41 (9.3%) | 34 (7.7%) | 0.185 |
| Stage II | 94 (21.2%) | 82 (18.5%) | ||
| Stage III | 54 (12.2%) | 74 (16.7%) | ||
| Stage IV | 34 (7.7%) | 30 (6.8%) | ||
| Primary therapy outcome, n (%) | PD | 10 (4.3%) | 15 (6.4%) | 0.214 |
| SD | 1 (0.4%) | 3 (1.3%) | ||
| PR | 4 (1.7%) | 8 (3.4%) | ||
| CR | 105 (44.7%) | 89 (37.9%) | ||
| Gender, n (%) | Female | 104 (22.9%) | 110 (24.2%) | 0.638 |
| Male | 123 (27.1%) | 117 (25.8%) | ||
| Age, n (%) | <=65 | 100 (22%) | 88 (19.4%) | 0.295 |
| > 65 | 127 (28%) | 139 (30.6%) | ||
| Lymphatic invasion, n (%) | NO | 137 (33.3%) | 111 (27%) | 0.048 |
| YES | 73 (17.8%) | 90 (21.9%) |